As a new investor I am at a loss to know why this little gem never goes anywhere

Is is a medical company with no debt, a profit!, minimal market capital and some interesting products.

We're in the shares4 schools contest and we'd like this babe to fly!

I bought into this company in 1999 at 7.25p!! hoping for it to explode to 1 and l'm still holding onto them for a miracle to happen one day even when it has first time gone into profit this year and has excellent products.I'm sure it will rise the moment l sell!!

I'm shocked at yet another fall, surely somebody kwows something?

All aboard?

I'm in for the ride, bought at 2.25p last year. Can't understand why market makers have not marked this one up sooner? Long term should be richly rewarded
IMHO. Lots of buying going on before 1pm, anyone seen a press tip? Cheers G.

Agree,things looking more positive last few days,volume well up today lots of fresh buyers,fast approaching 2 million trades up 37% reckon the new adviser Westhouse Securities also helps going forward.

About time. I'm craving some action!

Come on there must be some thoughts!

They have delivered a solid result which was widely expected only the mms can move the price up,how much longer is for us to ponder.In the near future we could hopefully see some bigger buys as the day punters will not buy only follow,or better still some directors giving the lead,also a tip would give a quick profit and run.Whatever happens Iam staying in as I bought these with a view of 4-5years and still confident we will get there.

Thanks!

Could get an update in Thursdays Shares mag,only way to get onto print apart from being tipped.

IC should also tip it

Looking for some comment from Shares tomorrow?

Lets hope they've done us proud in the past!

Sorry chaps no way.

Its a ramp. Its a very small company whose chairman has a very big mouth
and inflated ego.
He talked it up last year - same again this time but no-one is listening!!
Leave alone!!

It's a decent company with good fundamentals

No mention in Shares today try IC tomorrow.

I cannot see how the market makers can justify a spread so wide, so soon after the decent results, it hardly encourages trade does it?

Don't say the c word!

If this were a shell it'd be worth more.

A shell buying a medical provider and they'd be mega excited!

Why nothing?

The usual in todays IC, Expanding world sales,record order books and further growth this coming year what else is required,JRM its over to you!

I'm going to buy the damn company!

Last chance to get it at this market cap?

What do you mean?

5M+ for Sun,has to be a consideration for any interested buyer I think!

How much could I get????????????????????????????

It'll be in Shares tomorrow and my faith will be restored!

Yep keeping the faith,todays Shares says Surgical Innovations there is light at the end of the tunnel for this little supplier of surgical equipment with doubling of profits a record order book and more to come this year.
Lets hope a steady rise in the share price follows on from this, could be hearing some more news at the agm on June 2nd?

Nice for the good news!

Are we off?

Something warmed up a touch but try not to get to excited the general forcast was for the Sun to shine today,what Iam waiting for is the heatwave!

A chap I know from Leeds has it on good authority that
an aquisition is close to being completed.

I have also been told that moves are being made but I would be very
wary with a spread so wide.

Transco - Have they got the cash for an acquisition? No chance of a rights issue with the bombed out share price.

True - I hope!

Heading in the right direction Shares mag has given the Co a green arrow for the results and a positive outlook for the rest of this year.

Stayed level today, nearly as good as a rise in these markets?

I'M FEELING DOWN NOW!

Bargain day for Sun buyers today.2p going,going gone!

Thought last nights BBC news at ten on the CJD problem helped put the spot light onto Sun who are going to be one of the main preventors in the spread of this disease.Pictures of surgical instruments and blood plasma speak more clearly on the subject than we ever will?

We're still alone!

Never mind DDay 2nd June tomorrow AGM to offer another reason to climb aboard?

Good AGM more news shortly looking good?

Is it today?

It was yesterday and the information flow was very good.

Any thoughts?

The usual tick back following solid news,the Independent said today that SI boasts of continuing progress in all areas of its business, so we await a little longer for our re-rating.The mms stance on the spread will prevent smaller buyers for the time being but this I feel will finally change.ie larger investor,some director buys and a forthcoming press tip.The projected sales market for the Variglide product around 1/2bn with further contracts on the way speaks for itself,looking forward to the next tieup which was mentioned in a few days time at the AGM.

It's a long slog!

Keep applying the factor 30 while we wait?

Will Friday's buyer turn up today -We need a believer!

Nothing is going to move it I think until the mms are ready,perhaps the promised worldwide distribution deal to be announced shortly will do the trick?

It's about to bounce. The gap has narrowed and the buyers are arriving. It may not be much but who knows?

Yes just logged on surprising to see the number of buys after the mark down earlier today.Volume nearing 2m with a couple of nice buys thrown in,(our Friday buyer perhaps)talk of the world distribution deal also in the background nice to see a bit of interest today,practice for the real action to come.

charts are negative.this should be trading at under 1p in a few weeks

Some Director involvement this week prior to news of the worldwide sales agreement?

Todays Independent 1.11.O4
Surgical Innoations is being circled by brokers keen to snatch the company away from its current adviser,Westhouse.
A new broker it says could bring acquisition opportunities to the company, then SI shares could be worth watching.

Looks like the sun will shine now with news yesterday - deal with Rolls Royce.
Any one any comment!!! p/271

Yes it did!

Hurray!

Yes it did!

Nice one!

An interesting few days ahead of us..........Results next week should be fine and given the bumper start to the new year the share should move up. They're dancing around the year low is 50% possible in 10 days?

Fingers crossed.

Preliminary Results

Financial highlights
· Revenue of £7.64m (2011: £7.60m)
§ SI branded sales up 12.9% to £5.33m (2011: £4.73m) - representing 68% of total revenue
· Gross profit up 7.3% to £3.86m (2011: £3.60m)
· Gross margins improved to 50.5% (2011: 47.3%)
· Adjusted EBITDA (excluding exceptional items) of £2.89m (2011: £2.83m)
· Operating profit reduced to £1.32m (2011: £1.77m) - due to amortisation and exceptional costs
· Pre-tax profit reduced to £1.23m (2011: £1.71m)
· Adjusted earnings per share of 0.35p (2011: 0.44p)
· Net cash from operating activities of £612,000 (2011: £1.78m) - reflecting increase in working capital as a result of significant sales in December 2012

Operational highlights
· Strong second half sales with contracted orders in H2 of £5.62m up 85% on H1 (with c. £1m to be recognised in y/e 31 December 2013)
· US direct sales up 21.9% to £2.15m (2011: £1.76m) and are now 28.1% of total revenue (2011: 23.2%)
· 33% increase in unit sales of YelloPort+plus™ valves and swingtops
· YelloPort+plus™ cannula sales increased to 10,124 units (2011: 5,272 units) - will drive long term valve sales
· RGF grant of up to £5.05m to fund capital expansion strategy
· FDA approvals and US contracts provide a solid base for development of US strategy
· UK SI branded sales up 34.3% as more NHS hospitals convert to cost-saving Resposable® products
· New areas of MIS progressing well, particularly ultra-MIS (3mm) and hip arthroscopy

Surgical Innovations Group - Preliminary results

Audio Webcast

Senior Appointment of President of US Sales and Operations

Development agreement for Industrial application

Surgical Innovations Group plc (AIM: SUN), the designer and manufacturer of creative solutions for minimally invasive surgery ('MIS'), announces that it has received funding approval with its long standing industrial partner worth over GBP210,000. The funding will be used to develop a bespoke solution for a device delivery system to be used in the on-wing inspection of jet engines.

This new funding stream follows a feasibility study carried out in 2012 and revenues relating to the project will be in addition to existing revenues from the use of SI's patented articulating segment technology in jet engine inspection and maintenance. In 2012, revenues from SI's industrial division contributed GBP101,000 (2011: GBP70,000).

SI's Endoflex(TM) Industrial product has been specially adapted to industrial applications and is based on core technology developed over the years in its surgical devices business. The product is designed to deliver tools, devices, sensors and probes precisely and repeatedly to a given target zone in a variety of industrial applications. Endoflex(TM) Industrial can provide access into inaccessible or hazardous spaces and minimises the need to disassemble complicated equipment and systems.

Graham Bowland, Chief Executive Officer for Surgical Innovations, said: "I am delighted that we continue to develop this relationship with our key industrial partner. If the development project is successful, there is a good opportunity to roll-out a number of these devices in 2014. We continue to seek opportunities where SI's intellectual property can be adapted to provide industrial solutions for major international companies."

New US dealer

Surgical Innovations Group plc (AIM: SUN), the designer and manufacturer of creative solutions for minimally invasive surgery ('MIS'), announces the appointment of a US distributor, the first new US dealer since the appointment of Rick Barnett as President of US Sales and Operations.

The distributor will promote SI's Logi™ Range and YelloPort+plus™ products across Indiana, Kentucky and Ohio under the terms of a three year distribution agreement.

The established distributor is based in Indianapolis and through its dedicated sales team will cover in excess of 430 hospitals across the three designated US States.

Graham Bowland, Chief Executive Officer for Surgical Innovations, said: "This contract is evidence of SI's strategy to penetrate the US market and optimise the opportunity located there. Rick Barnett was appointed at the beginning of the month and in this short period of time has already secured this new distributor, which will help develop SI's presence in the US. Other US dealer agreements are in the pipeline and the market will be updated accordingly."


- ENDS -

Just gone back in........The interims next month should benefit from the profits too late to go into last year's finals!

Trading Update

SI has had a strong first six months of the financial year and continues to trade in line with market expectations for the full year. Revenues for the six months ended 30 June 2013 were 28% ahead of the same period last year at £3.88m (H1 2012: £3.02m) with an adjusted EBITDA for the period of £1.14m (H1 2012: £0.98m), a 16% improvement on the previous period. Profit before tax for the period of £567,000 (H1 2012: £181,000) has more than tripled.

Within the SI Brand business, the YelloPort+plus™ Port access system continued to gain UK market share as a cost effective solution for laparoscopic surgical procedures. Further to the update provided in the AGM Statement on 19 June 2013, two additional UK hospitals have converted to using our Resposable® products, one to the YelloPort+plus™ system and one to using Logi™Cut scissors. This takes the total number of hospitals converted this year to 25. The UK success of SI Branded products promotes adoption within our targeted export markets, with the US a primary focus for the Company where hospital cost reduction programmes are becoming an ever increasing phenomenon. Both orders and interest to date, ledby our newly appointed President of US Sales and Operations, are very encouraging as we expand our Brand exposure in the US.

The OEM business primarily focused on sales of instrumentation and retraction devices, driven by a demand from the existing OEM customer base. Revenues from Industrial applications will benefit from the recently announced development project with our long standing partner, due for completion at the end of 2013.

Hip Arthroscopy
SI are partnering with JRI, a leading UK Orthopaedic company to investigate how early stage osteoarthritis of the hip can be treated using minimally invasive techniques. The collaboration has recently been allocated a £390,000 grant from the TSB Biomedical Catalyst Fund to support the project, which will see SI further translate its access and articulation technologies into hip arthroscopy to enable and deliver new advanced therapeutic treatments.

Update on new facility
In January SI announced that it had formally signed the Regional Growth Fund ("RGF") Final Grant Offer Letter worth £5.05m. SI can now announce that the Board has formally approved the budget for the development of a new facility. The total cost of the building project will be funded through the RGF grant and the remainder by a commercial bank mortgage, with an estimated completion date of July 2015.

Three site locations, all situated on the Eastern side of Leeds, are being assessed for the 58,000sq ft facility which will incorporate a 10,000sq ft Clinical training centre. The Directors believe that a phased move to the new site will not have any impact on short term trading or profitability, but it is expected to bring significant operational efficiencies and the new building will be planned specifically to optimise SI's production capabilities. The Clinical training centre will act as a catalyst for innovation enabling international surgeons to develop best clinical practice in new areas of MIS, use and critique SI's latest medical device technologies and importantly enable SI to expand its development programme into new areas of MIS. The centre will combine classic training methods of laparoscopic work stations with cadaveric and dissection facilities and a simulated operating room. It is envisaged that SI will develop one of the premier facilities in the UK that will support the growing demand for clinical training both from home and abroad.

The Company will announce its interim results for the six months ended 30 June 2013 on Tuesday, 10 September 2013.

Interim Results

Financial highlights
· Revenues up 28.4% to £3.88m (H1 2012: £3.02m)
· Gross margins in core MIS business increased to 45.5% (H1 2012: 44.8%)
· EBITDA up 16.8% to £1.14m (H1 2012: £976,000*)
· Operating profit* up 18.2% to £623,000 (H1 2012: £527,000*)
· Pre-tax profit* up 19.4% to £567,000 (H1 2012: £475,000*)
· Reported pre-tax profit more than tripled to £567,000 (H1 2012: £181,000)
· Adjusted basic earnings per share of 0.12p (H1 2012: 0.09p)
· Net cash of £808,000 generated from operating activities (H1 2011: £888,000*)
*comparative adjusted to exclude H1 2012 exceptional costs of £294,000

Operational highlights
· Revenues from SI branded products up 37.7% to £2.93m (H1 2012: £2.13m)
· Revenues from OEM products down 5.2% to £0.85m (H1 2012: £0.89m)
· Strong sales of Resposable® instruments with continued disposable pull through to follow
· Revenues from SI branded disposable elements up 22.8% to £1.67m (H1 2012: £1.36m)
· Impressive 144% growth in UK SI branded product revenues to £809,000 (H1 2012: £331,000)

Post-period end highlights
· Two more distributors added to growing US distribution network
· Largest ever US order, in financial terms, for SI Branded products secured in H2

Beaufort Securities Speculative Buy 6.75 6.75 - - Initiates/Starts

This doesn't seem to be going anywhere and hasn't for a long time.?
Anyone have any ideas.

Stocking order under Surgioscopy agreement

Surgical Innovations Group plc (AIM: SUN), the designer and manufacturer of creative solutions for minimally invasive surgery ('MIS'), announces it has received and dispatched an initial stocking order from Surgioscopy worth a total of £141,000.

Trading Update

Surgical Innovations Group plc (AIM: SUN), the designer and manufacturer of creative solutions for minimally invasive surgery ('MIS'), provides the following trading update for the 12 months ended 31 December 2013.

Total revenues for the year ended 31 December 2013 will be £8.6m, a 13% increase against the previous year (2012: £7.6m). The Group's strategy for long term growth is the development of the SI Brand within the lucrative US market, underpinned by the appointment in May 2013 of an SI President of US Sales and Operations. The Group is therefore pleased to report a substantial increase of 75% in sales to the US of SI Branded products, through multiple new routes to market, clearly demonstrating our potential for growth and vindicating the high level of initial investment required. Overall, SI Branded product revenues have grown by 23% driven by the demand for our resposable technology.

Group profitability has been adversely affected by the combined effect of the US dollar exchange rate and more significantly the strategic investment during the second half of the year in manufacturing operations designed to streamline and improve process flows of individual product lines to enable and support the 75% growth in US revenues. As a result, the adjusted EBITDA (excluding exceptional items) for the year ended 31 December 2013 will be significantly below the reported number for the year ending December 2012 (2012: £2.9m).

The chairman has just bought 1000000 shares at 1.3p. I have bought 120000 shares which is showing as sell in the trade

After a nightmare 12 months is the good news starting to flow. At £6m market capital, a new board and established custmers will the sun soon shine?

I'd forgotten all about these.

Final results for year ended 31 December 2015

Surgical Innovations Group plc (AIM: SUN), the designer and manufacturer of innovative medical technology for minimally invasive surgery, reports significantly improved financial results for the year ended 31 December 2015. Revenues and margins continue to show encouraging progress, whilst significant reductions in net operating costs, working capital and net indebtedness have been achieved.

Highlights:
· Revenues up 36% to £5.47m (2014: £4.03m)
· Gross margin improvement in second half of the year (2015: 14.0%, H1: 8.4%, H2: 19.2%)
· Adjusted EBITDA of £0.24m (2014: Adjusted EBITDA loss of £0.05m)
· Inventory reduction programme well advanced (2015: £1.92m, 2014: £4.30m)
· Net cash generated from operations of £1.57m (2014: £0.69m net cash consumed)
· Net indebtedness reduced to £2.26m (2014: £3.33m)
· New Board of directors and key management team in place
· New sales channels and products coming on stream in 2016

Executive Chairman, Nigel Rogers, said:
"In a year of transition for the Company, there have been many positive changes. Relationships with our distribution partners have been strengthened and revenues have returned to growth on solid foundations. Manufacturing and operating costs have been reduced, and working capital has been brought into line with the current needs of what is now a cash generative business.

"With these changes delivered and a solid platform secured for future growth, we now have a Board and management structure intended to drive the future direction and development of the business.

"There has been further improvement in performance in the current financial year to date. Although there remain some challenges in building on the improvements delivered in 2015, we look forward with renewed confidence."

For further information please contact:

Revised Banking Facilities

Surgical Innovations Group plc (AIM: SUN), the designer and manufacturer of innovative technology for minimally invasive surgery, announces the revision of banking facilities made available by Yorkshire Bank ("the bank"). The existing term loan of approximately £1.70m has been repaid from available cash resources, and the bank has made available a Revolving Credit Facility of up to £1.30m for working capital and other purposes until 31 March 2020.

Nigel Rogers, Executive Chairman of SI Group, said: "Following the announcement yesterday concerning the conversion of Loan Notes, these changes to the financing structure are a major indicator of the successful transformation that the business has undergone over the last twelve months. The Company is now debt free, and can focus full attention on developing top line growth from additional products and sales channels, and the ongoing identification of suitable acquisition targets."